A closed-loop extracorporeal engineering concept.
Hemavive is developing a closed-loop extracorporeal engineering concept designed to bring controlled cell engineering closer to the patient — with the goal of reducing manufacturing complexity, improving standardization, and supporting scalable therapeutic workflows.
Patient, platform, product, patient.
A closed, extracorporeal approach to engineer hematopoietic and immune cells, held at a high level here — implementation detail is available under CDA / NDA.
Patient
Cells are drawn into a closed circuit at the point of care.
Closed-loop engineering platform
Controlled cell selection, processing and engineering inside a closed, automated workflow.
Engineered cell product
A characterized product, released against defined potency and safety criteria.
Return to patient
Infusion without the delay of centralized, single-patient manufacturing.
High-level schematic of Hemavive's future closed-loop extracorporeal engineering concept.
Targets, not results.
These are development targets, not demonstrated results. ECEP is in development and not yet clinically validated.
Protected platform concept.
Closed and distributed HSPC processing and engineering is covered by one of four provisional applications filed in 2026 — preserving future automation and manufacturing optionality.
See the full IP portfolioEngineering and manufacturing partners welcome.
Detailed technical materials are available under CDA / NDA.